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arc S. Penn, MD, PHD, Saif Anwaruddin, MD,
avi Nair, MD, Stephen Ellis, MD
leveland, Ohio
urrent treatments for acute myocardial infarction (AMI)
nvolving successful restoration of blood flow into the
nfarct-related artery either by percutaneous methods or by
brinolytic therapy have shown to be of benefit in reduction
f short-term mortality. While the advantages of these
eperfusion strategies are well established, they do not
ddress the loss of myocardium and adverse remodeling that
ccurs.
See page 2277
Beyond reperfusion therapy, the focus of treatment in
MI has shifted in the last few years toward the prevention
nd treatment of left ventricular dysfunction either through
egeneration or optimization of functional myocardium
ith the goal of improving outcomes in patients with
ardiovascular disease. While stem cells have been central to
his effort, the cell types used have been as varied as the
esults obtained (1). Controversy in stem cell-based thera-
ies exists regarding the questionable potential of adult stem
ells to differentiate into cardiac myocytes (2).
In this issue of the Journal, Hare et al. (3) present data
rom a phase I dose-escalation study of intravenous
llogeneic adult human mesenchymal stem cells (hMSCs)
fter AMI with the primary end point of safety at 6
onths. While this is a phase I safety study with a
imited number of patients making conclusions difficult,
t is an important study as it focuses on the use of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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hich has licensed these patent applications from the Cleveland Clinic. As such, he
eceives consulting fees and has the potential to receive equity and royalties. Dr. Nairi
s on the Medical Advisory Board of Boston Scientific and the Speaker’s Bureau of
anofi-Aventis, Pfizer, Merck, and Schering-Plough.llogeneic cells and a new delivery strategy. While Chen
t al. (4) previously reported the utility of autologous
one marrow hMSC coronary infusion post-AMI, this is
he first demonstration of an “off-the-shelf” intravenously
dministered allogeneic hMSC preparation. The study
eported on adverse events and effects of allogeneic
MSC from a single donor in 53 patients randomized in
double-blind placebo-controlled fashion. The authors
ere able to generate data suggesting the safety of these
ells post-infarction including a reduction in arrhythmic
vents in those receiving hMSCs.
Although the trial was not designed to show efficacy, the
uthors demonstrated a significant improvement in ejection
raction by echocardiography at 3 months but not at 6
onths, although some benefit was seen at 12 months by
agnetic resonance imaging. A similar catch-up phenom-
non was also observed in the placebo group that has been
oted previously in the BOOST (Bone Marrow Transfer to
nhance ST-Elevation Infarct Regeneration) trial (5). It is
nclear whether or not this is related to a time-limited
fficacy of stem cell therapy or simply to a more precise
maging modality in magnetic resonance imaging.
It is also interesting to note that the subset of patients
ith anterior wall AMI (n  26) had a more robust
esponse to hMSC therapy. This is consistent with obser-
ations from other studies demonstrating a relationship
etween response to treatment and extent of damage (6–8).
The findings of this study are potentially important as they
xtend the cells of interest for the early phase development of
ell therapy for preserving myocardial function (9). Further-
ore, this study demonstrates the use of allogeneic cells
ithout immunosuppression and defines a new minimally-
nvasive route of delivery for myocardial cell therapy in AMI.
erhaps just as importantly, this study and its findings validate
he approach and utility of pre-clinical studies undertaken to
efine mechanisms and test strategies for stem cell-based
yocardial repair.
The putative steps involved in stem cell-based myocar-
ial repair have been defined by multiple investigators
ver the past decade and are schematically represented in
igure 1. While the process is undoubtedly more detailed
han depicted, the study by Hare et al. (3) validates the
hysiology and biology predicted by the pre-clinical
tudies that came before it.
Whether cells are directly injected into the myocardium,
njected down the infarct-related vessel, or introduced via
ntravenous infusion, there are critical molecular signals
eleased by the newly injured myocardium that induce the
hemotaxis or homing of the stem cell to the area of
yocardial injury (10,11). The observation that patients
ith significant lung dysfunction garnered benefit further
upports the concept that hMSCs are capable of homing to
nd potentially repairing any tissue. Stromal cell-derived
actor-1 was the first myocardial stem cell homing factor
dentified (12), and more recently, monocyte chemoattrac-
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hMSC for Myocardial Repair December 8, 2009:2287–9ant protein-3 was identified as an hMSC homing factor
apable of homing systemically-delivered hMSCs to areas of
yocardial injury (13). Until this report by Hare et al. (3),
t had been controversial as to whether homing of
ystemically-delivered hMSCs would translate from rodents
o humans due to the greater blood volume and distances
rom injection site to the myocardium in humans. Interest-
ngly, in this study the maximal dose of hMSCs was 5
illion/kg, which is very close to the dose used in at least 1
at study of 6 million/kg (14).
After homing of the stem cell to the myocardium, the cell
eleases paracrine factors into the myocardial tissue leading
o preservation of cardiac myocytes, vascular growth, and
mproved left ventricular remodeling. Several studies have
dentified paracrine factors of interest including Sfrp2 (15),
tromal cell-derived factor-1 (14,16), and interleukin-10
17). Furthermore, studies have suggested strategies includ-
ng Akt overexpression (18) or direct genetic overexpression
14) that could be used in future studies to enhance the
ffects of hMSC-based therapy.
The data generated by Hare et al. (3) did not reveal any
vidence suggesting that hMSC dose affected myocardial
unction. Rather, their data suggest that infarct size medi-
ted the degree of benefit. This observation is consistent
ith the concept that infarct size, perhaps due to degree of
oming factor expression or perhaps number of cells at risk,
s more important for regulating hMSC-based myocardial
epair than the number of hMSCs in circulation.
Finally, there is the potential for prolonged engraftment
nd survival of hMSCs after intravenous infusion in AMI.
onsistent with hMSC homing, engraftment, and survival
n the myocardium is the observation of decreased arrhyth-
ic events in patients that received hMSCs compared with
ontrol subjects. Furthermore, it is interesting to note that
he inhibition of arrhythmias by hMSCs was dose-
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Figure 1 Schematic Representation of Putative Steps in Stemependent. hMSCs have been shown to decrease theotential for re-entrant arrhythmias in rodent models of
MI. This decrease in re-entrant arrhythmias was associ-
ted with the increased recruitment of cardiac stem cells to
he infarct border zone as well as the engraftment of
onnexin 43 and 45 expressing hMSCs in the infarct border
one (19). The fact that the dose of hMSCs inversely
orrelated with the number of premature ventricular
ontractions and arrhythmic events is consistent with the
re-clinical findings that the functional electrical size of
he infarct is independent from the mechanical size of the
nfarct (16) and can be modulated by engraftment of cells
apable of conducting action potentials (19).
In summary, the study by Hare et al. (3) clinically tested
nd validated the concepts of hMSC homing, and paracrine
actor and cell-associated effects on the mechanical and
lectrical properties of myocardial repair. This study repre-
ents an important step along the path toward defining
trategies for optimization of left ventricular function after
MI. With only modest observed benefits with initial
tudies of cell therapy, many questions remain, but there is
xcitement in what the future holds with regard to advances
n this field. Hare et al. (3) are to be congratulated on the
ompletion of this highly novel protocol that serves to
ighlight that the careful translation of well-founded pre-
linical strategies can be done safely and offers hope for
mproved patient outcomes in the future.
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leveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195.
-mail: pennm@ccf.org.
EFERENCES
1. Abdel-Latif A, Bolli R, Tleyjeh IM, et al. Adult bone marrow-derived
actor
e
Long-term
Engraftment
Infarct 
zone
ased Myocardial Repair in Acute Myocardial Infarctionne F
leascells for cardiac repair: a systematic review and meta-analysis. Arch
Intern Med 2007;167:989–97.
11
1
1
1
1
1
1
1
1
K
2289JACC Vol. 54, No. 24, 2009 Penn et al.
December 8, 2009:2287–9 hMSC for Myocardial Repair2. Leri A, Kajstura J, Anversa P, Frishman WH. Myocardial regenera-
tion and stem cell repair. Curr Probl Cardiol 2008;33:91–153.
3. Hare JM, Traverse JH, Henry TD, et al. A randomized, double-blind,
placebo-controlled, dose-escalation study of intravenous adult human
mesenchymal stem cells (prochymal) after acute myocardial infarction.
J Am Coll Cardiol 2009;54:2277–86.
4. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of
intracoronary transplantation of autologous bone marrow mesenchy-
mal stem cell in patients with acute myocardial infarction. Am J
Cardiol 2004;94:92–5.
5. Meyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell
transfer after myocardial infarction: eighteen months’ follow-up data from
the randomized, controlled BOOST (BOne marrOw transfer to enhance
ST-elevation infarct regeneration) trial. Circulation 2006;113:1287–94.
6. Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-
derived progenitor cells in acute myocardial infarction. N Engl J Med
2006;355:1210–21.
7. Janssens S, Dubois C, Bogaert J, et al. Autologous bone marrow-
derived stem-cell transfer in patients with ST-segment elevation
myocardial infarction: double-blind, randomised controlled trial. Lan-
cet 2006;367:113–21.
8. Penn MS. Stem-cell therapy after acute myocardial infarction: the
focus should be on those at risk. Lancet 2006;367:87–8.
9. Penn MS, Mangi AA. Genetic enhancement of stem cell engraftment,
survival, and efficacy. Circ Res 2008;102:1471–82.
0. Penn MS, Zhang M, Deglurkar I, Topol EJ. Role of stem cell homing
in myocardial regeneration. Int J Cardiol 2004;95 Suppl 1:S23–5.
1. Tang YL, Zhu W, Cheng M, et al. Hypoxic preconditioning
enhances the benefit of cardiac progenitor-cell therapy for treat- cment of myocardial infarction by inducing CXCR4 expression. Circ
Res 2009;104:1209–16.
2. Askari A, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived
factor-1 on stem cell homing and tissue regeneration in ischemic
cardiomyopathy. Lancet 2003;362:697–703.
3. Schenk S, Mal N, Finan A, et al. Monocyte chemotactic protein-3 is
a myocardial mesenchymal stem cell homing factor. Stem Cells
2007;25:245–51.
4. Zhang M, Mal N, Kiedrowski M, et al. SDF-1 expression by
mesenchymal stem cells results in trophic support of cardiac myocytes
following myocardial infarction. FASEB J 2007;21:3197–207.
5. Zhang Z, Deb A, Zhang Z, et al. Secreted frizzled related protein 2
protects cells from apoptosis by blocking the effect of canonical Wnt3a.
J Mol Cell Cardiol 2009;46:370–7.
6. Deglurkar I, Mal N, Mills WR, et al. Mechanical and electrical effects
of cell-based gene therapy for ischemic cardiomyopathy are indepen-
dent. Hum Gene Ther 2006;17:1144–51.
7. Burchfield JS, Iwasaki M, Koyanagi M, et al. Interleukin-10 from
transplanted bone marrow mononuclear cells contributes to cardiac
protection after myocardial infarction. Circ Res 2008;103:203–11.
8. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells
modified with Akt prevent remodeling and restore performance of
infarcted hearts. Nat Med 2003;9:1195–201.
9. Mills WR, Mal N, Kiedrowski MJ, et al. Stem cell therapy enhances
electrical viability in myocardial infarction. J Mol Cell Cardiol 2007;
42:304–14.
ey Words: myocardial infarction y allogeneic y mesenchymal stem
ells y magnetic resonance imaging y echocardiography.
